IL253824A0 - Pharmaceutical formulations of c1 esterase inhibitor - Google Patents

Pharmaceutical formulations of c1 esterase inhibitor

Info

Publication number
IL253824A0
IL253824A0 IL253824A IL25382417A IL253824A0 IL 253824 A0 IL253824 A0 IL 253824A0 IL 253824 A IL253824 A IL 253824A IL 25382417 A IL25382417 A IL 25382417A IL 253824 A0 IL253824 A0 IL 253824A0
Authority
IL
Israel
Prior art keywords
pharmaceutical formulations
esterase inhibitor
esterase
inhibitor
formulations
Prior art date
Application number
IL253824A
Other languages
English (en)
Hebrew (he)
Inventor
Hubert Metzner
Wolfram Schaefer
Frauke May
Ernst-Juergen Kanzy
Ingo Pragst
Original Assignee
Csl Behring Gmbh
Hubert Metzner
Wolfram Schaefer
Frauke May
Kanzy Ernst Juergen
Ingo Pragst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Gmbh, Hubert Metzner, Wolfram Schaefer, Frauke May, Kanzy Ernst Juergen, Ingo Pragst filed Critical Csl Behring Gmbh
Publication of IL253824A0 publication Critical patent/IL253824A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL253824A 2015-02-20 2017-08-03 Pharmaceutical formulations of c1 esterase inhibitor IL253824A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15156010 2015-02-20
PCT/EP2016/053559 WO2016131958A1 (en) 2015-02-20 2016-02-19 Pharmaceutical formulations of c1 esterase inhibitor

Publications (1)

Publication Number Publication Date
IL253824A0 true IL253824A0 (en) 2017-09-28

Family

ID=52573617

Family Applications (1)

Application Number Title Priority Date Filing Date
IL253824A IL253824A0 (en) 2015-02-20 2017-08-03 Pharmaceutical formulations of c1 esterase inhibitor

Country Status (13)

Country Link
US (1) US20180036394A1 (OSRAM)
EP (1) EP3258911A1 (OSRAM)
JP (1) JP6516855B2 (OSRAM)
KR (1) KR20170118856A (OSRAM)
CN (1) CN107257683A (OSRAM)
AU (1) AU2016221627A1 (OSRAM)
BR (1) BR112017017685A2 (OSRAM)
CA (1) CA2977090A1 (OSRAM)
IL (1) IL253824A0 (OSRAM)
MX (1) MX2017010323A (OSRAM)
RU (1) RU2017132449A (OSRAM)
SG (1) SG11201706019XA (OSRAM)
WO (1) WO2016131958A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109562149A (zh) 2016-08-05 2019-04-02 德国杰特贝林生物制品有限公司 C1酯酶抑制剂的药物制剂
BR112019023737A2 (pt) * 2017-05-16 2020-05-26 Octapharma Ag Preparação de inibidor de c1-esterase (c1-inh), kit que consiste em um primeiro receptáculo contendo a preparação de c1-inh, kit que consiste em uma seringa pré-cheia com a preparação de c1-inh, kit que consiste em um dispositivo adequado para aplicação subcutânea, tal como um injetor no corpo e uso de histidina para aumentar a biodisponibilidade de c1-inh administrado por via subcutânea
CN120381522A (zh) * 2025-04-02 2025-07-29 南方医科大学南方医院 一种治疗肝硬化门脉高压的化合物及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2758076B1 (en) * 2011-09-24 2018-12-12 CSL Behring GmbH Combination therapy using immunoglobulin and c1-inhibitor
DE202014011208U1 (de) * 2013-03-15 2018-08-23 Shire Viropharma Incorporated C1-INH Zusammensetzungen für die Vorbeugung und Behandlung von Störungen, die mit C1-Esterasehemmer-Defizienz assoziiert sind

Also Published As

Publication number Publication date
RU2017132449A3 (OSRAM) 2019-09-05
MX2017010323A (es) 2017-12-07
JP6516855B2 (ja) 2019-05-22
EP3258911A1 (en) 2017-12-27
KR20170118856A (ko) 2017-10-25
US20180036394A1 (en) 2018-02-08
CA2977090A1 (en) 2016-08-25
JP2018509398A (ja) 2018-04-05
AU2016221627A1 (en) 2017-08-17
RU2017132449A (ru) 2019-03-21
WO2016131958A1 (en) 2016-08-25
BR112017017685A2 (pt) 2018-04-10
CN107257683A (zh) 2017-10-17
SG11201706019XA (en) 2017-09-28

Similar Documents

Publication Publication Date Title
EP3191096A4 (en) Human dosing of phosphatase inhibitor
PL3116491T3 (pl) Kompozycje farmaceutyczne związków terapeutycznie aktywnych
IL256491A (en) Pharmaceutical formulations
IL265856A (en) Preparations for the administration of aflornithine
PT3474822T (pt) Formulações de brincidofovir
GB201522764D0 (en) Formulations of phosphate derivatives
IL256115A (en) Pharmaceutical formulations of injectable lapmoline
IL272857A (en) Cofanalisib formulations
IL254794A0 (en) Pharmaceutical formulations
IL267279A (en) Pharmaceutical formulations of suvorexant
IL253824A0 (en) Pharmaceutical formulations of c1 esterase inhibitor
EP3270911A4 (en) Pharmaceutical compositions of dimethyl fumarate
PT3678644T (pt) Formulações de copanlisib
ZA201803032B (en) Pharmaceutical compositions of dimethyl fumarate
ZA201705329B (en) Pharmaceutical formulations of racecadotril
HK40120600A (zh) 布林西多福韦的制剂
HK40115807A (zh) 布林西多福韦的制剂
EP3302461A4 (en) PHARMACEUTICAL COMPOSITIONS OF DIMETHYLFUMARATE
HK1242191A1 (zh) C1酯酶抑制剂的药物制剂
HK40014181A (en) Pharmaceutical formulations of suvorexant
HK40005624A (en) Formulations of brincidofovir
AU2015903172A0 (en) Inhibitors of necroptosis
GB201417646D0 (en) Formulations of phosphate derivatives
AU2015900416A0 (en) Inhibitors of necroptosis